Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyruvate dehydrogenase phosphatase catalytic subunit 2 (PDP2) is a mitochondrial enzyme and member of the protein phosphatase 2C (PP2C) family that catalyzes the dephosphorylation and reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex (PDC)[2][3]. Through this action, PDP2 plays a critical role in regulating the conversion of pyruvate to acetyl-CoA, thereby linking glycolysis with the tricarboxylic acid (TCA) cycle and fatty acid synthesis pathways. Basal activity of PDP2 is required to restore PDC activity after it has been inhibited by phosphorylation, supporting cellular energy production, especially during high metabolic demand. Mutations or deficiencies in this enzyme have been associated with metabolic disorders and are implicated in regulation of immune cell function and, potentially, in the pathology of cancer[3].
Activation via dephosphorylation of the pyruvate dehydrogenase complex (PDC) E1 alpha subunit, counteracting the inactivating phosphorylation by pyruvate dehydrogenase kinases (PDKs)[2][3] Drugs targeting this class, if they existed, would likely act as phosphatase modulators
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate dehydrogenase phosphatase catalytic subunit 2 (PDP2).